| 8:40-9:00 |
Registration |
| 9:00-9:10 |
Opening
Remarks |
Shinji
Harada
[Vice-president, Kumamoto University] |
| Session
I |
9:10-9:55
〔45〕 |
| Chair:
Hiroaki Mitsuya |
9:10-9:55
【45】 |
O-1-01 |
Michael
D. Miller
Merck Research Laboratories, USA
|
HIV Drug Discovery:
Past, Present, and Future |
|
Session
II |
9:55-10:35
〔40〕 |
| Chair:
Shinichi Oka |
| 9:55-10:35 【40】 |
O-1-02 |
Hiroaki
Mitsuya
Kumamoto University, Japan |
Development of
HIV-1 Chemotheraputics in the Era of "HIV-1 To Be Defeated" |
| 10:35-10:50
〔15〕 |
Coffee
Break |
| Session
III |
10:50-12:05
〔75〕 |
| Chair:
Masafumi Takiguchi |
| 10:50-11:35 【45】 |
O-1-03 |
Tomas
Hanke
University of Oxford, UK |
The 2nd generation
conserved region mosaic vaccine against HIV-1. |
| 11:35-12:05 【30】 |
O-1-04 |
Tetsuro
Matano
NIID / Kumamoto University, Japan |
Depletion of
vaccine-induced CD107a- CD4+ T cells following SIV infection |
| 12:05-13:30
〔85〕 |
Lunch |
| Session
IV |
13:30-14:05
〔35〕 |
| Chair:
Tetsuro Matano |
| 13:30-14:05 【35】 |
O-1-05 |
Mark
S. de Souza
Cooper Human Systems, USA |
T cell dysregulation
at the intestinal mucosa and peripheral blood during early acute HIV
infection |
| Session
V |
14:05-14:40
〔35〕 |
| Chair:
Nobuo Sakaguchi |
| 14:05-14:40 【35】 |
O-1-06 |
Yoshio
Koyanagi
Kyoto University, Japan |
Conflicts and
benefits between primate lentiviruses and host restriction factors |
| Session
VI |
14:40-15:10
〔30〕 |
| Chair:
Hiroyuki Gatanaga |
| 14:40-15:10 【30】 |
O-1-07 |
Takamasa
Ueno
Kumamoto University, Japan |
Impaired Nef
function is associated with early control of HIV-1 viremia |
| 15:10-15:25
〔15〕 |
Coffee
Break |
| Session
VII |
15:25-16:40
〔75〕 |
| Chair:
Yorifumi Satou |
| 15:25-16:10 【45】 |
O-1-08 |
Mathias
Lichterfeld
Harvard Medical School, USA |
Cellular reservoirs
for HIV-1 long-term persistence despite antiretroviral therapy |
| 16:10-16:40 【30】 |
O-1-09 |
Seiji
Okada
Kumamoto University, Japan |
HIV-1 restriction
factor COMMD1 reinforces HIV-1 latent infection through IκB-α stabilization. |
| Session
VIII |
16:40-17:10
〔30〕 |
| Chair:
Kazuhisa Yoshimura |
| 16:40-17:10 【30】 |
O-1-10 |
Hiroyuki
Yamamoto
NIID, Japan |
In vivo
determinants of SIV neutralizing antibody induction |
| Session
IX |
17:10-17:40
〔30〕 |
| Chair:
Shinya Suzu |
| 17:10-17:40 【30】 |
O-1-11 |
Shuzo
Matsushita
Kumamoto University, Japan |
Therapeutic application
of neutralizing antibodies based on the recent data on complementary
and synergistic activities against a wide range of HIV-1 strains. |
